Зея купить METHADONE

______________

✅ ️Наши контакты (Telegram):✅ ️

✅ ️ ▲ ✅ ▲ ️✅ ▲ ️✅ ▲ ️✅ ▲ ✅ ️

______________

Как выбрать кунг для пикапа?

Зея купить METHADONE

The contents of the capsules are a mixture of granules and white or white powder with a slightly yellowish tinge of color. The pharmacokinetics of fluconazole are similar with intravenous administration and ingestion. Simultaneous food intake does not affect the absorption of fluconazole. The plasma concentration is proportional to the dose and reaches a maximum C max in 0. The maximum concentration of fluconazole in saliva when taking the capsule is reached after 4 hours. The volume of distribution is close to the total water content in the body. Fluconazole penetrates well into all body fluids. Concentrations of fluconazole in saliva and sputum are similar to its concentrations in blood plasma. In the stratum corneum, epidermis, dermis, and sweat fluid, high concentrations are reached that exceed plasma concentrations. Fluconazole accumulates in the stratum corneum. The clearance of fluconazole is proportional to the clearance of creatinine. No circulating metabolites were detected. A long half-life fr om blood plasma allows you to take fluconazole once for vaginal candidiasis and once a day or once a week for other indications. It was found that after a single use of fluconazole at a dose of 50 mg orally in elderly patients aged 65 years and older, some of whom simultaneously took diuretics With max was achieved after 1. Simultaneous use of diuretics did not cause a marked change in AUC and C max. Fluconazole, a triazole antifungal agent, is a powerful selective inhibitor of Sterol synthesis in the fungal cell. Fluconazole has demonstrated activity in vitro and in clinical infections against most of the following microorganisms: Candida albicans, Candida glabrata many strains are moderately sensitive , Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans. Fluconazole has been shown to be active in vitro against the following microorganisms, but its clinical significance is unknown: Candida dubliniensis, Candida guilliermondii, Candida kefyr, and Candida lusitaniae. When taken orally, fluconazole is active in various models of fungal infections in animals. The activity of the drug in opportunistic mycoses, including those caused by Candida spp, has been demonstrated. Fluconazole activity was also established in models of endemic mycoses in animals, including infections caused by Blastomyces dermatitides, Coccidioides immitis including intracranial infections and Histoplasma capsulatum in animals with normal and suppressed immunity. Fluconazole has a high specificity for fungal enzymes dependent on cytochrome P Point mutations in the ERG 11 gene encoding the target enzyme lead to a modification of the target and a decrease in affinity for azoles. Increasing the expression of the ERG 11 gene leads to the production of high concentrations of the target enzyme, which creates the need for increasing the concentration of fluconazole in the intracellular fluid to suppress all the enzyme molecules in the cell. The second significant mechanism of resistance is the active removal of fluconazole from the intracellular space by activating two types of transporters involved in the active removal efflux of drugs from the fungal cell. These transporters include the main mediator encoded by MDR multiple drug resistance genes, and the ATP-binding cassette Transporter superfamily encoded by CDR genes genes for resistance of Candida fungi to azole antimicotics. Overexpression of the MDR gene leads to resistance to fluconazole, while overexpression of CDR genes can lead to resistance to various azoles. Resistance to Candida glabrata is usually mediated by overexpression of the CDR gene, which leads to resistance to many azoles. Candida krusei should be considered as resistant to fluconazole. The mechanism of resistance is associated with reduced sensitivity of the target enzyme to the inhibitory effect of fluconazole. Fluconazole is used for the treatment of mucosal candidiasis oropharyngeal candidiasis and esophageal candidiasis , invasive candidiasis, cryptococcal meningitis, and the prevention of candidiasis infections in patients with a weakened immune system. Fluconazole can be used as a maintenance therapy to prevent recurrence of cryptococcal meningitis in children with a high risk of recurrence. Adequate and controlled studies of the use of fluconazole in pregnant women have not been conducted. The following developmental disorders were noted: brachycephaly, impaired development of the facial part of the skull, impaired formation of the cranial vault, cleft palate, curvature of the femurs, thinning and elongation of the ribs, arthrogryposis, and congenital heart defects. Currently, there is no evidence to link these congenital abnormalities with the use of low doses of fluconazole mg once for the treatment of vulvovaginal candidiasis in the first trimester of pregnancy. During pregnancy, the use of fluconazole should be avoided, except in cases of severe and potentially life-threatening fungal infections, when the expected benefit of treatment exceeds the possible risk to the fetus. Women of childbearing age should use contraception. Fluconazole is found in breast milk in concentrations close to plasma, so its use in women during breastfeeding is not recommended. Therapy can be started before receiving the results of seeding and other laboratory tests. However, antifungal therapy should be changed accordingly when the results of these studies become known. When transferring a patient from intravenous to oral administration of the drug or Vice versa, changes in the daily dose are not required. The daily dose of fluconazole depends on the nature and severity of the fungal infection. For infections that require repeated administration of the drug, treatment should continue until clinical or laboratory signs of active fungal infection disappear. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually need supportive therapy to prevent relapses of infection. In case of cryptococcal meningitis and cryptococcal infections of other localization, the drug is usually used at a dose of mg on the first day, and then treatment is continued at a dose of mg once a day. The duration of treatment for cryptococcal infections depends on the presence of clinical and mycological effects; in cryptococcal meningitis, treatment is usually continued for at least 68 weeks. In cases of life-threatening infections, the daily dose can be increased to mg. For some infections, especially those involving the meninges, a dose of mg per day may be considered. The duration of therapy is determined individually, it can last up to 2 years; it is months for coccidioidomycosis, months for paracoccidioidomycosis, months for sporotrichosis and months for histoplasmosis. The duration of therapy depends on the clinical effectiveness. The General recommendation for the duration of treatment of candidaemia is 2 weeks after the first negative result of blood culture and the disappearance of signs and symptoms of candidaemia. For acute vaginal carlilse , candidal balanitis fluconazole administered once orally at a dose of mg. To reduce the frequency of relapses of vaginal candidiasis, the drug can be used at a dose of mg every three days for a total of 3 doses on the 1st, 4th and 7th day , then a maintenance dose of mg once a week. The maintenance dose can be used up to 6 months. For the prevention of Candida infections in patients with long-term neutropenia, the recommended dose of fluconazole is 2, mg once a day, depending on the risk of developing a fungal infection. For patients with a high risk of generalized infection, for example, with severe or long-lasting neutropenia, the recommended dose is mg once a day. Fluconazole is used a few days before the expected development of neutropenia and, after increasing the number of neutrophils more than in mm 3 , treatment is continued for another 7 days. As with similar infections in adults, the duration of treatment depends on the clinical and mycological effect. For children, the daily dose of the drug should not exceed that for adults. Fluconazole is used daily once a day. If it is not possible to correctly use the dosage form of the drug fluconazole in capsules in children, consider replacing it with other dosage forms of the drug a powder for preparing a suspension for oral administration or a solution for intravenous administration in equivalent doses. In the absence of signs of renal failure, fluconazole is used in the usual dose. Patients with renal insufficiency creatinine clearance No dose changes are required for a single dose. In patients including children with impaired renal function with repeated use of the drug, an initial shock dose of 50 mg to mg should be administered, after which the daily dose depending on the indication is set according to the following table:. On the day when dialysis is not performed, patients should receive a reduced depending on creatinine clearance dose of the drug. In children with impaired renal function, the daily dose of the drug should be reduced in the same proportion as in adults , in accordance with the severity of renal failure. From the side of metabolism: rarely decreased appetite; rarely increased concentration of cholesterol and triglycerides in blood plasma, hypokalemia. On the part of the nervous system: often headache; rarely dizziness, convulsions, changes in taste, paresthesia; rarely tremor. On the part of the cardiovascular system: rarely ventricular tachycardia of the pirouette type, prolongation of the QT interval on the ECG. From the gastrointestinal tract: often abdominal pain, vomiting, diarrhea, nausea; infrequently constipation, dyspepsia, flatulence, dryness of the oral mucosa. From the liver and biliary tract: often increased activity of aminotransferases aspartate aminotransferase ACT , alanine aminotransferase AJIT and alkaline phosphatase; infrequently cholestasis, jaundice, increased bilirubin concentration; rarely liver failure, hepatotoxicity, in some cases fatal, hepatocellular necrosis, hepatitis, hepatocellular damage, liver dysfunction. From the skin and subcutaneous fat: often rash; infrequently toxidermia, urticaria, skin itching, increased sweating; rarely toxic epidermal necrolysis, Stevens-Johnson syndrome, open generalized exanthematous pustules, exfoliative dermatitis, angioedema, facial edema, alopecia. In some patients, especially those with serious diseases such as HIV infection or cancer, changes in blood parameters, kidney function and liver function have been observed during treatment with fluconazole and similar drugs see Special instructions , but the clinical significance of these changes and their relationship to treatment have not been established. Single or repeated administration of fluconazole at a dose of 50 mg does not affect the metabolism of phenazone Antipyrine when taken simultaneously. Cisapride: when using fluconazole and cisapride simultaneously, undesirable reactions from the heart are possible, including ventricular tachysystolic arrhythmia of the pirouette type torsade de pointes. The use of fluconazole at a dose of mg once a day and cisapride at a dose of 20 mg 4 times a day leads to a marked increase in plasma concentrations of cisapride and an increase in the QT interval on the ECG. Simultaneous administration of cisapride and fluconazole is contraindicated. Terfenadine: with the simultaneous use of azole antifungal agents and terfenadine, serious arrhythmias may occur as a result of increasing the QT interval. Astemizol: concomitant use of fluconazole with astemizol or other drugs whose metabolism is carried out by the cytochrome P system may be accompanied by an increase in serum concentrations of these agents. Increased concentrations of astemizole in blood plasma can lead to an elongation of the QT interval and, in some cases, to the development of ventricular tachysystolic arrhythmia of the pirouette type torsade de pointes. Simultaneous use of astemizole and fluconazole is contraindicated. Pimozide: although not conducted relevant studies in vitro or in vivo, coadministration of fluconazole and pimozide may result in inhibition of pimozide metabolism. In turn, an increase in plasma concentrations of pimoside can lead to an elongation of the QT interval and, in some cases, the development of ventricular tachysystolic arrhythmia of the pirouette type torsade de pointes. Coadministration of fluconazole and pimozide is contraindicated. Quinidine: although no relevant in vitro or in vivo studies have been conducted, concomitant use of fluconazole and quinidine may also lead to inhibition of quinidine metabolism. The use of quinidine is associated with prolongation of the QT interval and in some cases with the development of ventricular tachysystolic arrhythmia of the pirouette type torsade de pointes. Simultaneous use of quinidine and fluconazole is contraindicated. Erythromycin: concomitant use of fluconazole and erythromycin potentially leads to an increased risk of cardiotoxicity prolongation of the QT interval , torsade de pointes and, consequently, sudden cardiac death. Concomitant use of fluconazole and erythromycin is contraindicated. Amiodarone: concomitant use of fluconazole and amiodarone may result in inhibition of amiodarone metabolism. The use of amiodarone was associated with prolongation of the QT interval. Concomitant use of fluconazole and amiodarone is contraindicated see section Contraindications. Caution should be exercised and possible dose adjustments should be made when the following drugs and fluconazole are used simultaneously:. The effect of this degree of severity does not require changing the dosage regimen of fluconazole in patients receiving diuretics at the same time, but the doctor should take this into account. In patients taking rifampicin at the same time, it is necessary to consider the feasibility of increasing the dose of fluconazole. In addition, in addition to the following effects, there is a risk of increased plasma concentrations of other drugs metabolized by the isoenzymes CYP 2 C 9, CYP 2 C 19 and CYP 3 A 4 when taken simultaneously with fluconazole. In this regard, caution should be exercised when using these drugs simultaneously, and if necessary, such combinations of patients should be under careful medical supervision. It should be borne in mind that the inhibitory effect of fluconazole persists for 45 days after discontinuation of the drug due to a long half-life. Alfentanil: there is a decrease in clearance and distribution volume, and an increase in the half-life of Alfentanil. This may be due to inhibition of the CYP 3 a 4 isoenzyme by fluconazole. You may need to adjust the dose of Alfentanil. Amitriptyline, nortriptyline: increasing the effect. Amphotericin B: in mouse studies including those with immunosuppression , the following results were noted: a small additive antifungal effect in systemic infection caused by C. The clinical significance of these results is not clear. In patients receiving coumarin anticoagulants, it is necessary to constantly monitor the prothrombin time during therapy and for 8 days after simultaneous use. Azithromycin: with simultaneous oral administration of fluconazole in a single dose of mg with azithromycin in a single dose of mg, there is no pronounced pharmacokinetic interaction between both drugs. Benzodiazepines short-acting : after oral administration of midazolam, fluconazole significantly increases the concentration of midazolam and psychomotor effects, and this effect is more pronounced after oral administration of fluconazole than when it is administered intravenously. If concomitant therapy with benzodiazepines is necessary, patients taking fluconazole should be monitored to assess the appropriateness of an appropriate reduction in the dose of benzodiazepine. You may need to adjust the dose of triazolam. The risk of carbamazepine toxicity should be considered. Calcium channel blockers: some calcium channel antagonists nifedipine, isradipine, amlodipine, verapamil, and felodipine are metabolized by the CYP 3 A 4 isoenzyme. Fluconazole increases the systemic exposure of the calcium channel antagonists. It is recommended to control the development of side effects. When using fluconazole and cyclosporine simultaneously, it is recommended to monitor the concentration of cyclosporine in the blood. Cyclophosphamide: with the simultaneous use of cyclophosphamide and fluconazole, there is an increase in serum concentrations of bilirubin and creatinine. This combination is acceptable given the risk of increasing bilirubin and creatinine concentrations. Fentanyl: there is a report of one fatal outcome, possibly associated with simultaneous administration of fentanyl and fluconazole. It is assumed that the violations are associated with fentanyl intoxication. Fluconazole has been shown to significantly lengthen the elimination time of fentanyl. It should be borne in mind that increasing the concentration of fentanyl can lead to respiratory depression. Halofantrin: fluconazole may increase the plasma concentration of halofantrin due to inhibition of the CYP 3 A 4 isoenzyme. When used simultaneously with fluconazole, as with other antifungal drugs of the azole series, it is possible to develop ventricular tachysystolic arrhythmia of the pirouette type, so their joint use is not recommended. If simultaneous therapy with these drugs is necessary, patients should be monitored to detect symptoms of myopathy and rhabdomyolysis. It is necessary to control the concentration of creatinine kinase. If there is a significant increase in creatinine kinase concentration or if development is diagnosed or suspected. Losartan: fluconazole inhibits the metabolism of losartan to its active metabolite E 74 , which is responsible for most of the effects associated with angiotensin - II receptor antagonism. Regular monitoring of blood pressure is necessary. Methadone: fluconazole may increase the plasma concentration of methadone. You may need to adjust the methadone dose. In this combination, it is possible to reduce the dose of celecoxib by half. Despite the lack of targeted studies, fluconazole may increase the systemic exposure of other NSAIDs metabolized by the CYP 2 C 9 isoenzyme for example, naproxen, lornoxicam, meloxicam, diclofenac. When using NSAIDs and fluconazole at the same time, patients should be under close medical supervision in order to identify and control adverse events and manifestations of toxicity associated with NSAIDs. Thus, repeated use of fluconazole in these doses is unlikely to affect the effectiveness of a combined oral contraceptive. Phenytoin: simultaneous use of fluconazole and phenytoin may be accompanied by a clinically significant increase in the concentration of phenytoin. If it is necessary to use both drugs simultaneously, the concentration of phenytoin should be monitored and its dose adjusted accordingly in order to ensure therapeutic concentration in the blood serum. Prednisone: there is a report on the development of acute adrenal cortex insufficiency in a patient after liver transplantation against the background of discontinuation of fluconazole after a three-month course of therapy. Presumably, discontinuation of fluconazole therapy caused an increase in the activity of the CYP 3 A 4 isoenzyme, which led to increased prednisone metabolism. Patients receiving combination therapy with prednisone and fluconazole should be under close medical supervision when discontinuing fluconazole in order to assess the state of the adrenal cortex. Cases of uveitis have been described with simultaneous use of fluconazole and rifabutin. Patients receiving rifabutin and fluconazole simultaneously should be carefully monitored. You may need to adjust the dose of saquinavir. Sirolimus: increased sirolimus concentration in blood plasma, presumably due to inhibition of sirolimus metabolism through inhibition of the CYP 3 A 4 isoenzyme and P-glycoprotein. Sulfonylureas: fluconazole, when taken simultaneously, leads to an increase in the half-life of oral sulfonylureas chlorpropamide, glibenclamide, glipizide and tolbutamide. Patients with diabetes mellitus can be prescribed concomitant use of fluconazole and oral sulfonylureas, but the possibility of hypoglycemia should be taken into account, in addition, regular monitoring of blood glucose and, if necessary, correction of the dose of sulfonylureas. Tacrolimus: simultaneous use of fluconazole and tacrolimus inside leads to an increase in serum concentrations of the latter by 5 times due to inhibition of tacrolimus metabolism occurring in the intestine by means of the CYP 3 A 4 isoenzyme. Significant changes in the pharmacokinetics of drugs were not observed when using tacrolimus intravenously. Cases of nephrotoxicity are described. Patients who simultaneously take tacrolimus orally and fluconazole should be carefully monitored. The dose of tacrolimus should be adjusted depending on the degree of increase in its concentration in the blood. When prescribing fluconazole to patients taking theophylline in high doses, or patients with an increased risk of developing the toxic effect of theophylline, it is necessary to monitor the appearance of symptoms of an overdose of theophylline and, if necessary, adjust therapy accordingly. Periwinkle alkaloid: despite the lack of targeted studies, it is suggested that fluconazole may increase the concentration of periwinkle alkaloids for example, vincristine and vinblastine in blood plasma and thus lead to neurotoxicity, which may be associated with the inhibition of the CYP 3 A 4 isoenzyme. Vitamin A: there is a report of one case of adverse reactions from the Central nervous system CNS in the form of a pseudo-brain tumor with the simultaneous use of completely transretinoic acid and fluconazole, which disappeared after discontinuation of fluconazole. The use of this combination is possible, but you should keep in mind the possibility of undesirable reactions from the Central nervous system. Patients receiving this combination should be monitored to detect side effects of zidovudine. Simultaneous use of voriconazole and fluconazole is not recommended. Studies of the interaction of oral forms of fluconazole when it is taken simultaneously with food, cimetidine, antacids, as well as after total irradiation of the body to prepare for bone marrow transplantation have shown that these factors do not have a clinically significant effect on the absorption of fluconazole. Tofacitinib: the exposure of tofacitinib increases when it is co-administered with drugs that are both moderate inhibitors of the CYP 3 A 4 isoenzyme and potent inhibitors of the CYP 2 C 19 isoenzyme for example, fluconazole. You may need to adjust the dose of tofacitinib. Ivacaftor: when used simultaneously with ivacaftor, a cystic fibrosis regulator of transmembrane conductivity CFTR stimulator, there was a 3-fold increase in ivacaftor exposure and a 1. Patients who are simultaneously taking moderate CYP 3 a inhibitors, such as fluconazole and erythromycin, are recommended to reduce the dose of ivacaftor to mg once a day. These interactions are established with repeated use of fluconazole; interactions with drugs as a result of a single administration of fluconazole are not known. Doctors should keep in mind that interaction with other drugs has not been specifically studied, but it is possible. There are reports of an overdose of fluconazole, and in one case, a year-old patient infected with the human immunodeficiency virus developed hallucinations and paranoid behavior after taking mg of the drug. The patient was hospitalized; his condition returned to normal within 48 hours. In the case of an overdose, symptomatic treatment including supportive measures and gastric lavage can give an adequate effect. Cases of superinfection caused by Candida strains other than Candida albicans that often have natural resistance to fluconazole for example, Candida krusei have been reported. In such cases, alternative antifungal therapy may be required. In rare cases, the use of fluconazole was accompanied by toxic liver changes, including fatal ones, mainly in patients with serious concomitant diseases. In the case of hepatotoxic effects associated with the use of fluconazole, there was no clear dependence on the total daily dose of the drug, the duration of therapy, gender and age of the patient. The hepatotoxic effect of the drug was usually reversible; signs of it disappeared after discontinuation of therapy. Patients who have impaired liver function during treatment with the drug should be monitored for signs of more serious liver damage. If there are clinical signs or symptoms of liver damage that may be associated with the use of fluconazole, the drug should be discontinued. During treatment with fluconazole, patients in rare cases developed exfoliative skin lesions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. AIDS patients are more likely to develop severe skin reactions when using many drugs. If a patient has a superficial fungal infection during treatment that can be associated with the use of fluconazole, the drug should be discontinued. If a rash appears in patients with invasive or systemic fungal infections, they should be carefully monitored and the drug should be discontinued if bullous lesions or multiform exudative erythema appear. When using fluconazole, an increase in the QT interval and flickering or fluttering of the ventricles were very rarely observed in patients with severe diseases with multiple risk factors, such as organic heart disease, electrolyte imbalance, and concomitant therapy that contributes to the development of such disorders. Therefore, in such patients with potentially proarrhythmic conditions, fluconazole should be used with caution. Patients with liver, heart and kidney diseases should consult a doctor before using the drug. When using fluconazole mg for vaginal candidiasis, patients should be warned that improvement in symptoms is usually observed after 24 hours, but it sometimes takes several days for them to disappear completely. If symptoms persist for several days, you should consult a doctor. When using the drug, it is necessary to take into account the possibility of dizziness and seizures. Information about prescription drugs is for professionals only. The information provided should not be used by patients to make an independent decision on the use of the presented drugs and cannot serve as a substitute for a full-time consultation with a doctor. A description of the active substances of the drug is provided. The scientific information provided is generalized and cannot be used to decide on the possibility of using a specific drug. The appearance of the product may differ from the photos on the site. N7 Russia. Fluconazole 50mg caps. N7 Russia Prescription drug. Рецептурный препарат. Product is available in pharmacies:. Add to cart. All products in the order are reserved for 24 hours, after that the order is automatically canceled. Brief information General description Manufacturer: Производство Медикаментов ООО Active substance Флуконазол There are contraindications, specialist advice is required The appearance of the product may differ from the photos on the site. Composition Composition per capsule Active substance: Fluconazole Composition of the capsule shell 0 Gelatin The body of the capsule is white colour, the cap of the capsule is white. Fluconazole is indicated for the prevention of the following diseases in adults: Relapses of cryptococcal meningitis in patients at high risk of relapse Relapses of oropharyngeal candidiasis and esophageal candidiasis in HIV-infected patients with a high risk of relapse To reduce the frequency of recurrent vaginal candidiasis 4 or more episodes per year For the prevention of Candida infections in patients with long-term neutropenia such as patients with hemoblastosis undergoing chemotherapy, or patients undergoing hematopoietic stem cell transplantation. Fluconazole is indicated for the treatment of children. Capsules are swallowed whole. Use in adults 1. Treatment of mucosal candidiasis In oropharyngeal candidiasis, the saturating dose is 2, mg on the first day, followed by a dose of , mg once a day for days. If necessary, patients with severe suppression of immune function can continue treatment for a longer time. In chronic atrophic oral candidiasis associated with the wearing of dentures, the drug is usually used in a dose of 50 mg once a day for 14 days in combination with local antiseptic agents for the treatment of the prosthesis. In patients with severe immune system dysfunction, longer periods of therapy can be used. In chronic skin and mucous candidiasis, mg per day is used for up to 28 days of treatment. Depending on the severity of the infection treatment or the accompanying immune system disorder and infection, longer periods of therapy can be used. In esophageal candidiasis, the saturating dose is 2, mg on the first day, followed by a dose of , mg per day. The course of treatment is days before achieving remission of esophageal candidiasis. To prevent relapses of oropharyngeal candidiasis in HIV-infected patients with a high risk of relapses, fluconazole is used mg per day or mg 3 times a week for an indefinite period of time in patients with chronically reduced immunity. To prevent recurrence of esophageal candidiasis in HIV-infected patients with a high risk of recurrence, fluconazole is used mg per day or mg 3 times a week for an indefinite period of time in patients with chronically reduced immunity. Treatment of dermatomycosis For skin infections, including stop dermatophytosis, torso dermatophytosis, inguinal dermatophytosis, and Candida infections, the recommended dose is mg once a week or 50 mg once a day. The duration of therapy is usually 24 weeks, with mycosis of the feet, longer therapy may be required up to 6 weeks. In multi-colored lichen, the recommended dose is mg once a week for 13 weeks. An alternative treatment regimen is to use the drug 50 mg once a day for 24 weeks. For onychomycosis, the recommended dose is mg once a week. Treatment should continue until the infected nail is replaced the uninfected nail grows. It usually takes 36 months and months, respectively, for the nails to grow again on the fingers and feet. However, the rate of growth can vary widely in different people, as well as depending on age. After successful treatment of long-lasting chronic infections, sometimes there is a change in the shape of the nails. Use in children As with similar infections in adults, the duration of treatment depends on the clinical and mycological effect. Use in the elderly In the absence of signs of renal failure, fluconazole is used in the usual dose. Patients with renal insufficiency creatinine clearance Use in patients with renal insufficiency No dose changes are required for a single dose. From the immune system: rarely anaphylaxis. From the side of the psyche: rarely drowsiness, insomnia. Violations of the organ of hearing and labyrinth disorders: rarely, vertigo. From the gastrointestinal tract: often abdominal pain, vomiting, diarrhea, nausea; infrequently constipation, dyspepsia, flatulence, dryness of the oral mucosa From the liver and biliary tract: often increased activity of aminotransferases aspartate aminotransferase ACT , alanine aminotransferase AJIT and alkaline phosphatase; infrequently cholestasis, jaundice, increased bilirubin concentration; rarely liver failure, hepatotoxicity, in some cases fatal, hepatocellular necrosis, hepatitis, hepatocellular damage, liver dysfunction. From the musculoskeletal system: rarely myalgia. Other: fatigue, weakness, fatigue, malaise, asthenia, fever. Concomitant use of fluconazole with the following drugs is contraindicated: Cisapride: when using fluconazole and cisapride simultaneously, undesirable reactions from the heart are possible, including ventricular tachysystolic arrhythmia of the pirouette type torsade de pointes. It is also necessary to evaluate the feasibility of correcting the dose of warfarin. If there is a significant increase in creatinine kinase concentration or if development is diagnosed or suspected myopathy or rhabdomyolysis, therapy with HMG-COA reductase inhibitors should be discontinued. As with other azoles, fluconazole can rarely cause anaphylactic reactions. Influence on the ability to drive vehicles, mechanisms When using the drug, it is necessary to take into account the possibility of dizziness and seizures. Capsules of 50 mg and mg. Флуконазол-Акрихин мг капс N1. This product is in 46 pharmacies, see all 1A Partizanskaya Street s. Ignatievskoe, Social pharmacy 17 pom Sh. Prescription drug. Флуконазол мг капс N1. Available in another region. The goods are available in pharmacies:. Town Pharmacy Catalog Basket 0. All pharmacies 1 Kantemirova Street Ajbolit с 8. Chigiri Social pharmacy с 8. Novotroitskoe Perekrestok pharmacy с 9. Ignatievskoe Tvoyaapteka с 8. Ignatievskoe Social pharmacy с 8.

Купить Говно Яхрома

Hydra спид(ы), фен Сызрань

Зея купить METHADONE

Энтеогены Шымкент

Форум себеж

Купить Марки Оленегорск